Drugs Channel
Topics & Medications
Quicklinks
Related Channels

Peginesatide Dosage

When determining an appropriate peginesatide dosage, your healthcare provider will take into consideration your weight, other similar medications you have taken, and various other factors. This medication comes as an injection that is given intravenously or subcutaneously once every four weeks. If the amount needs to be increased, it should be done gradually to avoid high hemoglobin levels.

In February 2013, peginesatide was pulled from the market (all of the product was recalled) to investigate reports of dangerous allergic reactions, including fatal anaphylactic reactions, which appear to be occurring more frequently than anticipated. This medication will not be available until further notice.
 

An Introduction to Your Dosage of Peginesatide

The dose of peginesatide (Omontys®) your healthcare provider recommends will vary, depending on a number of factors, including:
 
  • Your previous dosage of other similar medications
  • How you respond to peginesatide (as measured by blood tests)
  • Your weight.
 
As always, do not adjust your dose unless your healthcare provider specifically tells you to do so.
 

Peginesatide Dosing Guidelines

If you have not already been taking a different erythropoiesis-stimulating agent (ESA), the recommended starting dosage is based on your weight -- 0.04 mg per kg of body weight per month (about 0.018 mg per lb per month).
 
If you are switching to peginesatide from another ESA, such as epoetin alfa (Epogen®, Procrit®) or darbepoetin alfa (Aranesp®), your healthcare provider will calculate your starting peginesatide dosage based on your most current amount of epoetin alfa or darbepoetin alfa.
 
Your healthcare provider will check your progress frequently, using a blood test that measures the amount of hemoglobin in your blood. He or she will adjust your dose in order to gradually increase your hemoglobin to a safe level (too high can be just as dangerous as too low). Studies have shown that using ESAs, including peginesatide, to increase the hemoglobin above 11 g/dL increases the risk of death, serious heart problems, blood clots, and strokes. Studies have not found a dosage, dosing strategy, or hemoglobin target level that does not increase these risks.
 
Your dose should not be increased more frequently than once a month, in order to give peginesatide a chance to work. If your hemoglobin increases too quickly or too much, your healthcare provider should decrease your dose or stop it temporarily.
 
Peginesatide can be given as an injection under the skin (a subcutaneous injection) or as a slow injection into a vein (an intravenous, or IV, infusion) during dialysis.
 

Peginesatide Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.